Guidance for laboratories performing molecular pathology for cancer patients.
Guidance for laboratories performing molecular pathology for cancer patients.
复制标题
DOI：
10.1136/jclinpath-2014-202404
复制
发表时间：
2014-11
影响因子：
3.4
通讯作者：
Royal College of Pathologists
中科院分区：
文献类型：
--
作者：
Cree IA;Deans Z;Ligtenberg MJ;Normanno N;Edsjö A;Rouleau E;Solé F;Thunnissen E;Timens W;Schuuring E;Dequeker E;Murray S;Dietel M;Groenen P;Van Krieken JH;European Society of Pathology Task Force on Quality Assurance in Molecular Pathology;Royal College of Pathologists
分子检测正在成为癌症患者诊断的重要组成部分。实验室面临的挑战是满足这一需求，使用可靠的方法和流程确保患者及时收到准确的报告，作为治疗的基础。本文的目的是为分子病理学实验室的管理提供最低要求。此一般指南应通过针对不同肿瘤类型和测试的具体指南进行补充。分析前的考虑很重要，并且有必要仔细考虑样本的获取和到达实验室的方式。样品接收和处理遵循标准操作程序，但如果要进行分子测试，例如控制组织固定，可能需要进行一些改变。 DNA 和 RNA 提取可以标准化，并应定期检查输出的质量和数量。分析方法的选择取决于临床要求、所需的周转时间和可用的专业知识。内部质量控制、整个测试过程的定期内部审核、实验室认可以及持续参与外部质量评估计划是提供可靠服务的先决条件。分子病理学报告应准确传达临床医生治疗患者所需的信息，并提供足够的信息，以便正确解释结果。分子病理学正在迅速发展，这里涉及的许多主题需要进一步详细的基于证据的建议。
Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this paper is to provide minimum requirements for the management of molecular pathology laboratories. This general guidance should be augmented by the specific guidance available for different tumour types and tests. Preanalytical considerations are important, and careful consideration of the way in which specimens are obtained and reach the laboratory is necessary. Sample receipt and handling follow standard operating procedures, but some alterations may be necessary if molecular testing is to be performed, for instance to control tissue fixation. DNA and RNA extraction can be standardised and should be checked for quality and quantity of output on a regular basis. The choice of analytical method(s) depends on clinical requirements, desired turnaround time, and expertise available. Internal quality control, regular internal audit of the whole testing process, laboratory accreditation, and continual participation in external quality assessment schemes are prerequisites for delivery of a reliable service. A molecular pathology report should accurately convey the information the clinician needs to treat the patient with sufficient information to allow for correct interpretation of the result. Molecular pathology is developing rapidly, and further detailed evidence-based recommendations are required for many of the topics covered here.
登录
查看更多内容
影响因子：
8.8
作者：
Mead, R.;Duku, M.;Bhandari, P.;Cree, I. A.
通讯作者：
Cree, I. A.
影响因子：
3.5
作者：
Dijkstra, J. R.;Heideman, D. A. M.;van Krieken, J. H. J. M.
通讯作者：
van Krieken, J. H. J. M.
影响因子：
4.1
作者：
Dijkstra, Jeroen R.;Opdam, Frank J. M.;van Krieken, J. Han J. M.
通讯作者：
van Krieken, J. Han J. M.
癌细胞适应化学疗法。
影响因子：
3.8
作者：
Di Nicolantonio, F;Mercer, SJ;Knight, LA;Gabriel, FG;Whitehouse, PA;Sharma, S;Fernando, A;Glaysher, S;Di Palma, S;Johnson, P;Somers, SS;Toh, S;Higgins, B;Lamont, A;Gulliford, T;Hurren, J;Yiangou, C;Cree, IA
通讯作者：
Cree, IA
影响因子：
8.8
作者：
Glaysher, S.;Gabriel, F. G.;Cree, I. A.
通讯作者：
Cree, I. A.